Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 30.03.2026 1 Ann Oncol 3 Ann Surg Oncol 2 BMC Cancer 1 Breast Cancer 8 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 7 Breast Cancer Res Treat 1 Breast J 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Res 2 Cell 12 Clin Breast Cancer 1 Gene 1 Int J Cancer 3 J Natl Cancer Inst 2 J Surg Oncol 1 Mod Pathol 2 N Engl J Med 1 Nature 1 Oncogene 1 PLoS Genet 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Radiol Cardiothorac Imaging

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. GENTILE G, Gerosa R, de Azambuja E, Piccart-Gebhart M, et al
   20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.
   Ann Oncol. 2026;37:470-480.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. BOCCARDO F, Santori G, Fedre B, Fregatti P, et al
   LYMPHA Technique to Prevent Arm Lymphedema After Breast Cancer Treatment: A Single-Center Study Based on a 15-Year Follow-Up Period.
   Ann Surg Oncol. 2026 Mar 26. doi: 10.1245/s10434-026-19526.
   PubMed         Abstract available
   
   
3. WRIGHT GP, Thompson JL
   ASO Author Reflections: Reexamining Physical Examination in Modern Breast Cancer Survivorship.
   Ann Surg Oncol. 2026 Mar 23. doi: 10.1245/s10434-026-19399.
   PubMed        
   
   
4. MENEVEAU MO, Sevilimedu V, Le T, Eskreis-Winkler S, et al
   I?s Neoadjuvant Chemotherapy Justified When Triple-Negative Breast Cancer or HER2-Positive Breast Cancer Presents as >/=1 cm of Only Calcifications or as a Subcentimeter Mass with Surrounding Calcification?s?
   Ann Surg Oncol. 2026 Mar 22. doi: 10.1245/s10434-026-19475.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. FAN M, He S, Wan C, Zhang J, et al
   Joint synthesis of longitudinal MRI and enhanced prediction of neoadjuvant chemotherapy response in breast cancer: a multicohort study.
   BMC Cancer. 2026 Mar 24. doi: 10.1186/s12885-026-15889.
   PubMed        
   
   
6. VERDUIN RJT, van den Hurk CJG, van Maurik IS, Nota NM, et al
   Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial.
   BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15905.
   PubMed        
   
   

   
   Breast Cancer

7. WATANUKI R, Sakai H, Kimura Y, Yoshida A, et al
   Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case?control study (WJOG16722B).
   Breast Cancer. 2026 Mar 26. doi: 10.1007/s12282-026-01847.
   PubMed         Abstract available
   
   

   
   Breast Cancer (Dove Med Press)

8. ABSALAN F, Azizi R, Hakimi H, Shariat M, et al
   Systemic Immune Remodeling in Breast Cancer: Selective Enrichment of TNFR2(+) Circulating Lymphocytes in Breast Cancer.
   Breast Cancer (Dove Med Press). 2026;18:563472.
   PubMed         Abstract available
   
   
9. KHAIRANI AF, Alhaq KF, Herriyanto RI, Fauzi MB, et al
   Keratin as a Potential Prognostic Biomarker for Breast Cancer Progression: An Evidence-Synthesizing Narrative Review.
   Breast Cancer (Dove Med Press). 2026;18:578887.
   PubMed         Abstract available
   
   
10. LEE H, Kim G, Kim M, Kim JL, et al
    Identification and Validation of a Novel Theranostic Target in Triple Negative Breast Cancer with Transcriptomics and Protein Analyses.
    Breast Cancer (Dove Med Press). 2026;18:568001.
    PubMed         Abstract available
    
    
11. TANG Y, Yang Z, Ye Z, Su H, et al
    Identification of Potential Therapeutic Targets for Xihuang Pill in Breast Cancer: A Mendelian Randomization and Experimental Study.
    Breast Cancer (Dove Med Press). 2026;18:572244.
    PubMed         Abstract available
    
    
12. WICHTOWSKI M, Adamska M, Lojko-Dankowska A, Gil L, et al
    Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer - A Case Report and Experience-Driven Strategy.
    Breast Cancer (Dove Med Press). 2026;18:536327.
    PubMed         Abstract available
    
    
13. TIAN Z, Chen X, Li H, Li C, et al
    Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:565375.
    PubMed         Abstract available
    
    
14. CANGUR C, Bulbul B, Yegen IT, Ucun B, et al
    Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey.
    Breast Cancer (Dove Med Press). 2026;18:571246.
    PubMed         Abstract available
    
    
15. LAN Y, Zheng Y, Zhu Y, Xie X, et al
    Development and Preliminary Validation of a Wearable Tumor Treating Fields Device for Breast Cancer Therapy.
    Breast Cancer (Dove Med Press). 2026;18:568389.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

16. SAVARIDAS SL, Marshall A, Ali K, Astley SM, et al
    Change in mammographic density as a potential predictor of cancer recurrence after breast conservation surgery and adjuvant endocrine therapy: results of the MEDICI study.
    Breast Cancer Res. 2026;28:62.
    PubMed         Abstract available
    
    
17. LIU S, Liu A, Zhang L, Li J, et al
    CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer.
    Breast Cancer Res. 2026 Mar 22. doi: 10.1186/s13058-026-02248.
    PubMed        
    
    

    
    Breast Cancer Res Treat

18. BAXTER SM, McShane CM, McIntosh SA, Bennett D, et al
    House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland.
    Breast Cancer Res Treat. 2026;216:33.
    PubMed         Abstract available
    
    
19. DE MOURA LEITE L, de Almeida GR, Tavares MC, Cesca MG, et al
    Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.
    Breast Cancer Res Treat. 2026;216:34.
    PubMed         Abstract available
    
    
20. MORRAR D, Ross D, Razavi P, Brogi E, et al
    Rb expression in metastatic ER-positive breast cancer: implications for precision oncology.
    Breast Cancer Res Treat. 2026;216:36.
    PubMed         Abstract available
    
    
21. ZHU Y, Hadidchi R, Nguyen HQ, Hariharan S, et al
    Automated calculation of background parenchymal enhancement as a biomarker of treatment responses and recurrence-free survival in breast cancer.
    Breast Cancer Res Treat. 2026;216:35.
    PubMed         Abstract available
    
    
22. HAWKINS LA, Rumano RP, Smith SS, Beverly-Hery CM, et al
    Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice.
    Breast Cancer Res Treat. 2026;216:38.
    PubMed         Abstract available
    
    
23. YANG EJ, Kim HS, Jeon HR, Suh MR, et al
    Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial.
    Breast Cancer Res Treat. 2026;216:37.
    PubMed         Abstract available
    
    
24. AMNIOUEL S, Jafri MS
    Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer.
    Breast Cancer Res Treat. 2026;217:1.
    PubMed         Abstract available
    
    

    
    Breast J

25. ALTUNKUREK SZ, Yesilyurt E, Hassan Mohamed S
    The Effect of Breast Cancer and Breast Self-Examination Health Education on Awareness, Beliefs, and Practices of Female Students at the Faculty of Health Sciences of a University in Somalia.
    Breast J. 2026;2026:e8854280.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

26. CABRERA-LOPEZ M, Angeles-Llerenas A, de la Vara-Salazar E, Sanchez GI, et al
    Association of levonorgestrel-containing emergency contraceptive pills with breast cancer in premenopausal Latin American women: the PRECAMA study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    
27. POTT J, Mason AM, Salo V, Kettunen J, et al
    PCSK9 and breast cancer survival: a Mendelian Randomization study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Lett

28. YUAN Q, Zhang H, Zhang N, Qian Y, et al
    BPHL promotes TNBC stemness by resolving R-loops via POLR2A lactylation inhibition and BARD1-mediated ubiquitination.
    Cancer Lett. 2026;645:218388.
    PubMed         Abstract available
    
    

    
    Cancer Res

29. GAO A, Khatri PH, Ma G, Liu P, et al
    Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.
    Cancer Res. 2026 Mar 26. doi: 10.1158/0008-5472.CAN-25-4701.
    PubMed         Abstract available
    
    

    
    Cell

30. GAO H, Chakraborty G, Lee-Lim AP, Mo Q, et al
    The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites.
    Cell. 2026 Mar 21:S0092-8674(26)00327-2. doi: 10.1016/j.cell.2026.
    PubMed        
    
    
31. YAO B, Liu X, Ruan K, Fang X, et al
    Divergent tumor immunity determined by bacteria-cancer cell engagement.
    Cell. 2026;189:1748-1767.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

32. SHAHRIARIRAD R, Kumar N, Vijayasekaran A
    Systemic Evaluation of Quality, Readability, and Integrity of Online Breast Reconstruction Resources.
    Clin Breast Cancer. 2026;26:133-146.
    PubMed         Abstract available
    
    
33. SINCLAIR M, Mann GB, Kozul C, Park A, et al
    Quality of Life and Fear of Recurrence or Progression in Women With DCIS Who Did and Did Not Receive Radiotherapy.
    Clin Breast Cancer. 2026;26:235-246.
    PubMed         Abstract available
    
    
34. O'BRIEN DR, Boe L, Barrio A, Mueller B, et al
    Accelerated Partial Breast Irradiation (APBI) For Ductal Carcinoma In Situ.
    Clin Breast Cancer. 2026;26:147-153.
    PubMed         Abstract available
    
    
35. CARDOSO JHCO, de Lara ICA, Sobreira LER, Lobo AOM, et al
    Retraction notice to "Omitting axillary lymph node dissection is associated with an increased risk of regional recurrence in early stage breast cancer: a systematic review and meta-analysis of randomized clinical trials" [Clinical Breast Cancer 24 (20
    Clin Breast Cancer. 2026;26:98.
    PubMed        
    
    
36. LIN M, Jiang Y, Chen Y, Yang H, et al
    Multidimensional Regulatory Mechanisms of Extracellular Matrix Stiffness in Breast Cancer and Its Prospects for Clinical Translation.
    Clin Breast Cancer. 2026;26:85-97.
    PubMed         Abstract available
    
    
37. GIFFONI M M MATA D, Fernandes I, Smith-Uffen M, Browne C, et al
    Reduced Survival Outcomes in Socioeconomically Disadvantaged Women With HER2-Negative Breast Cancer Undergoing Chemotherapy in Canada.
    Clin Breast Cancer. 2026 Feb 24:S1526-8209(26)00030.
    PubMed         Abstract available
    
    
38. STUMP A, Gordon M, Becker E, Ding K, et al
    Impact of COVID-19 Pandemic on Completion of Radiation Therapy After Lumpectomy for Early-Stage Breast Cancer.
    Clin Breast Cancer. 2026 Feb 26:S1526-8209(26)00019.
    PubMed         Abstract available
    
    
39. ALAM MT, Fardaush J, Khan SA, Proma AY, et al
    Association of XPC rs2228001, ESR2 rs1256030, and rs4986938 Gene Polymorphisms With Breast Cancer Risk in Bangladeshi Women: A Case-Control Study.
    Clin Breast Cancer. 2026;26:73-84.
    PubMed         Abstract available
    
    
40. MISHRA A, Deo S, Bagla C, Bhoriwal S, et al
    Lymph Node Ratio as an Independent Prognostic Factor in Breast Cancer: A Retrospective Study of 4060 Patients Undergoing Axillary Lymph Node Dissection.
    Clin Breast Cancer. 2026;26:67-72.
    PubMed         Abstract available
    
    
41. JUNG WF, Rothchild E, Kasabian AK
    Evaluating Breast Reconstruction Equity Using the Social Vulnerability Index: A Single-Institution Cohort Study.
    Clin Breast Cancer. 2026;26:119-127.
    PubMed         Abstract available
    
    
42. YU Y, Kim DK, Jones NE, Shaikh NI, et al
    Association of Limited English Proficiency With Completion of the Reconstructive Paradigm in Implant-Based Breast Reconstruction.
    Clin Breast Cancer. 2026;26:65-73.
    PubMed         Abstract available
    
    
43. BHARDWAJ S, Jaffer S
    A Comparative Analysis of HER2 Immunohistochemistry in Core Biopsy Versus Excision in the Era of HER2 ;;Low'' Breast Cancers.
    Clin Breast Cancer. 2026;26:39-43.
    PubMed         Abstract available
    
    

    
    Gene

44. LIU H, Huo YX, Rao Y, Wang SH, et al
    SRPRB can regulate proliferation and migration in Triple-Negative breast cancer cells.
    Gene. 2026;994:150122.
    PubMed         Abstract available
    
    

    
    Int J Cancer

45. GROENEWEG R, van Ravesteyn NT, Kregting LM, Ursin G, et al
    Quality-adjusted life years in the presence and absence of organized mammographic screening using data from BreastScreen Norway.
    Int J Cancer. 2026;158:2537-2548.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

46. ABOUMRAD M, Joshu C, Jackson J, Visvanathan K, et al
    Antidepressant adherence and breast cancer recurrence risk in women with major depressive disorder: a retrospective cohort.
    J Natl Cancer Inst. 2026 Mar 21:djag076. doi: 10.1093.
    PubMed         Abstract available
    
    
47. KWAN ML, D'Addario L, Lee C, Roh JM, et al
    Differences in breast cancer survival across Asian American ethnicities compared with non-Latina White females in Kaiser Permanente Northern California.
    J Natl Cancer Inst. 2026 Mar 26:djag062. doi: 10.1093.
    PubMed         Abstract available
    
    
48. KAUL M, Scott CG, Wadzinske A, Banerjee I, et al
    Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model.
    J Natl Cancer Inst. 2026 Mar 26:djag083. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

49. VIEIRA RADC, Coelho EG, Cunha JRD, Neto RC, et al
    Surgical Quality Indicators for Locally Advanced Breast Carcinoma: Suggestions From the Brazilian Society of Surgical Oncology.
    J Surg Oncol. 2026;133:249-258.
    PubMed         Abstract available
    
    
50. CAROCO TV, Reis J, Saraiva RP, Angelo MD, et al
    Efficacy of Aminocaproic Acid in Preventing Postoperative Hematoma in Breast Cancer Surgery: A Prospective Study.
    J Surg Oncol. 2026 Mar 23. doi: 10.1002/jso.70244.
    PubMed         Abstract available
    
    

    
    Mod Pathol

51. KRINGS G, Bean GR, Hosfield EM, Rowe JJ, et al
    Genetic Profiling of Mammary Periductal Stromal Tumors With Histologic Correlation Highlights High-Grade and Low-Grade Groups and Similarities to Phyllodes Tumors.
    Mod Pathol. 2026;39:100961.
    PubMed         Abstract available
    
    

    
    N Engl J Med

52. OLIVIER T, Schnog JB
    Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2026;394:620.
    PubMed        
    
    
53. CORTES J, Tolaney SM
    Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2026;394:620-621.
    PubMed        
    
    

    
    Nature

54. SAHIN U, Schmidt M, Derhovanessian E, Cortini A, et al
    Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC.
    Nature. 2026;651:1088-1096.
    PubMed         Abstract available
    
    

    
    Oncogene

55. WANG X, Li G, Wu J, Fu B, et al
    TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation.
    Oncogene. 2026 Mar 24. doi: 10.1038/s41388-026-03728.
    PubMed         Abstract available
    
    

    
    PLoS Genet

56. AARTS MT, Nordin A, Cantu C, van Boxtel AL, et al
    Mechanistic dissection of GRHL2 and PR transcriptional co-regulation in breast cells.
    PLoS Genet. 2026;22:e1012088.
    PubMed         Abstract available
    
    

    
    PLoS One

57. JENA M, Dehuri S, Cho SB
    SGA-DT: An adaptive fusion framework for missing data imputation and interpretable healthcare classification.
    PLoS One. 2026;21:e0343619.
    PubMed         Abstract available
    
    
58. DAY S, Harries J, Sawula B, Payne A, et al
    Navigating cancer: Insights from patient journey mapping.
    PLoS One. 2026;21:e0327113.
    PubMed         Abstract available
    
    
59. AHMAD S, Qazi S, Bano N, Uddin R, et al
    Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer.
    PLoS One. 2026;21:e0344028.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

60. CUI W, Xiao H, Wen X, Li C, et al
    Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression.
    Proc Natl Acad Sci U S A. 2026;123:e2514681123.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

61. TENG X, Ma J, Zhang J, Zhao M, et al
    Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Radiol Artif Intell. 2026 Mar 25:e250734. doi: 10.1148/ryai.250734.
    PubMed         Abstract available
    
    

    
    Radiol Cardiothorac Imaging

62. DEEG J, Swoboda M, Lacaita PG, Barbieri F, et al
    Impact of Radiation Therapy for Breast Cancer on the Coronary Artery Disease Profile at Cardiac CT.
    Radiol Cardiothorac Imaging. 2026;8:e250415.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum